Loading clinical trials...
Loading clinical trials...
A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and Nonalcoholic Fatty Liver Disease
Conditions
Interventions
TLC-2716 Dose 1
TLC-2716 Dose 2
+1 more
Locations
4
Mexico
OrsoBio Research Site
Guadalajara, Jalisco, Mexico
OrsoBio Research Site
Zapopan, Jalisco, Mexico
OrsoBio Research Site
Mexico City, Mexico City, Mexico
OrsoBio Research Site
Mexico City, Mexico City, Mexico
Start Date
August 12, 2024
Primary Completion Date
June 1, 2025
Completion Date
September 1, 2025
Last Updated
April 3, 2025
NCT07237750
NCT06822790
NCT05495139
NCT00983463
NCT02581085
NCT05583344
Lead Sponsor
OrsoBio, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions